Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data

Prime Medicine, Inc. (NASDAQ:PRME) is among the 12 Best Genomics Stocks to Invest In.

Prime Medicine Announces NEJM Publication Of PM359 Data

Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition. Prime Editing for p47-phox Chronic Granulomatous Disease is a publication that presents preliminary data from two individuals treated in a Phase 1/2 trial intended to assess safety, biological function, and initial effectiveness in both adult and pediatric participants. Prior CGD-defining problems were seen in both patients. Each had fast neutrophil engraftment, with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30. Following infusion, neither patient experienced any new CGD-related problems or serious concurrent illnesses. The observed toxicities were compatible with busulfan-based conditioning, and no clinically relevant adverse events linked to PM359 were documented.

As reported by TheFly, LifeSci Capital started covering Prime Medicine, Inc. (NASDAQ:PRME) on December 23, 2025, with an Outperform rating and a $6 price target. LifeSci Capital noted that the business is creating one-and-done gene editing treatments for conditions like cystic fibrosis, Wilson’s disease, and alpha-1 antitrypsin deficiency that have an extensive unmet demand. The firm stated it is optimistic about the potential in Wilson’s disease and alpha-1 antitrypsin deficiency.

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology business focused on providing genetic medicines to treat diseases through the use of gene editing technology, known as Prime Editing.

While we acknowledge the risk and potential of PRME as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRME and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None